Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $11.50.

Several analysts recently weighed in on KPTI shares. Royal Bank Of Canada reiterated an “outperform” rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. Piper Sandler dropped their target price on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Weiss Ratings cut Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. HC Wainwright downgraded Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a report on Friday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th.

Karyopharm Therapeutics Trading Down 2.6%

Karyopharm Therapeutics stock opened at $1.91 on Thursday. The firm has a market cap of $43.28 million, a P/E ratio of -0.13 and a beta of 0.89. Karyopharm Therapeutics has a 1-year low of $1.80 and a 1-year high of $10.99. The firm has a 50-day moving average of $8.47 and a 200-day moving average of $8.08.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, May 14th. The company reported ($1.24) EPS for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.21. The business had revenue of $35.07 million for the quarter, compared to the consensus estimate of $31.40 million. Research analysts forecast that Karyopharm Therapeutics will post -4.29 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of KPTI. Corient Private Wealth LLC purchased a new position in Karyopharm Therapeutics during the fourth quarter worth $74,000. Baird Financial Group Inc. bought a new position in Karyopharm Therapeutics in the 2nd quarter valued at $45,000. Hsbc Holdings PLC purchased a new stake in Karyopharm Therapeutics in the first quarter worth $66,000. Tudor Investment Corp ET AL bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $95,000. Finally, XTX Topco Ltd purchased a new stake in shares of Karyopharm Therapeutics during the second quarter valued at $56,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.